💊the latest FDA approval
AstraZeneca’s Lynparza Label Now Includes Breast Cancer.
AstraZeneca, plc AZN and partner Merck MRK announced that the FDA has approved the supplemental New Drug Application (sNDA) for Lynparza seeking approval for label expansion in metastatic breast cancer. Lynparza is presently marketed for advanced ovarian cancer.
With the latest FDA approval, Lynparza can now be used to treat previously treated (chemotherapy) patients with HER2-negative metastatic breast cancer, harboring germline BRCA mutations.
Moreover, the drug is also approved in patients with HR+ breast cancer who were treated with an endocrine therapy or were ineligible for the same.January 15, 2018
– Zacks.com
https://www.zacks.com/stock/news/288858/astrazenecas-lynparza-label-now-includes-breast-cancer?cid=CS-ZC-FT-288858